UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

During the 2024-2025 academic year, the UConn School of Pharmacy fielded a team that placed sixth out of 70 schools or ...

The 71st Fortune 500 ranks America’s largest companies by 2024 fiscal year revenue. Key healthcare takeaways from the most recent listing from Fortune, released June 2: 1. The list includes 12 ...

Investors flocked to shares of NRG as the energy supplier boosted capacity. UnitedHealth stock slumped, and the company’s CEO ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...